UK Biobank is a health resource with unparalleled research opportunities. UK Biobank data will enable the scientific community to understand, diagnose, treat and prevent life-changing diseases– including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. UK Biobank is following the health and well-being of 500,000 volunteer participants and provides anonymised health information to approved researchers in the UK and overseas, from academia and industry.
About the Partnership
Together with deCODE in Iceland, the Sanger Institute will read and assemble the whole genome sequences of 500,000 UK Biobank volunteers. The Sanger Institute will sequence 225,000 whole human genomes.
This is one of the most ambitious sequencing efforts of whole human genomes ever undertaken. Sequencing will take place over 27 months, starting in September 2019. This builds on the ongoing success of the pilot programme, known as the Vanguard project, in which Sanger is sequencing 10 per cent of the cohort - 50,000 genomes of UK Biobank volunteers.
A dataset of this magnitude will be incredibly powerful for understanding the genetic architecture that contributes to diseases such as cancer, cardiovascular diseases, depression and dementia.
The £200m project is being funded by a collaboration between the government’s research and innovation agency, UK Research and Innovation (UKRI), Wellcome, Amgen, AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson*.
The first tranche of data is expected to comprise of up to 125,000 sequences, anticipated to be accessible to all in Spring 2021 and at the same time the 50,000 Vanguard sequences will be available.
The expectation is that sequence data for the entire cohort of UK Biobank participants would become generally accessible by early 2023.
* Contract entered by Janssen Biotech Inc., one of the Pharmaceutical Companies of Johnson & Johnson; collaboration facilitated by the Johnson & Johnson EMEA Innovation center in London, UK
The Illumina High Throughput Sequencing team runs the Institute's large scale sequencing facility. It is unique in scale and processing capability. As such, and for more than 20 years, this team has produced most of the institute's sequencing data across a variety of platforms.
Our Faculty work closely with our Scientific Operations teams which are responsible for all data production pipelines at the Institute. There are three main facilities; DNA Operations , Animal and Mouse Pipelines and Cellular Operations. We have smaller core facilities for Protein Mass Spectrometry, Cytometry, Cytogenetics and Single Cell Genomics.
The Human Genetics Programme is driving a step-change in our understanding of genetic causes and biological mechanisms of disease susceptibility and progression, focusing on developmental disorders and diseases of the blood and immune system. We integrate population-scale genetics, longitudinal clinical data, and large-scale genetic perturbation studies in cellular model systems. We aim to transform the clinical utility of human genetic variation.